Translation of Targeted Therapies in Multiple Myeloma

@inproceedings{Anderson2012TranslationOT,
  title={Translation of Targeted Therapies in Multiple Myeloma},
  author={Kenneth C. Anderson},
  year={2012}
}
Multiple myeloma (MM) is a remarkable example of rapid bench-to-bedside translation in new drug development. The proteasome inhibitor bortezomib and immunomodulatory drug lenalidomide targeted MM cells in the bone marrow (BM) microenvironment to overcome conventional drug resistance in laboratory and animal models and were rapidly translated into clinical trials demonstrating their efficacy in patients with relapsed and then newly diagnosed MM, with a doubling of the median survival as a direct… CONTINUE READING

Similar Papers

References

Publications referenced by this paper.
SHOWING 1-10 OF 75 REFERENCES

A randomized phase 2 trial of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

P Richardson, E Blood, CS Mitsiades
  • Blood 15:3458-3464,
  • 2006
VIEW 11 EXCERPTS
HIGHLY INFLUENTIAL

The IMiD CC 5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

P Richardson, R Schlossman, E Weller
  • Blood 100:3063-3067,
  • 2002
VIEW 11 EXCERPTS
HIGHLY INFLUENTIAL

Advances in the biology and treatment of bone disease in multiple myeloma.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2011